Biopharmaceutical Tubing Market Report 2026

Biopharmaceutical Tubing Market Overview

• Biopharmaceutical Tubing market size has reached to $4.79 billion in 2025 • Expected to grow to $8.12 billion in 2030 at a compound annual growth rate (CAGR) of 11.1% • Growth Driver: Rising Personalized Medicine Drives Growth in the Biopharmaceutical Tubing Market • Market Trend: Advancements In Biopharmaceutical Tubing With Customizable Bioabsorbable Solutions For Enhanced Performance • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biopharmaceutical Tubing Market?

Biopharmaceutical tubing refers to specialized tubing used in the manufacturing and handling of biopharmaceutical products. It is designed to meet stringent standards for sterility, biocompatibility, and precision to ensure the safe and effective handling of sensitive substances throughout the manufacturing and administration processes. The main products in the biopharmaceutical tubing market are silicone tubing, polyvinyl chloride (PVC) tubing, polyolefin tubing, and thermoplastic elastomer tubing. Silicone biopharmaceutical tubing refers to flexible, high-purity tubing made from silicone rubber, designed for use in the biopharmaceutical industry. The various manufacturing processes include extrusion, vulcanization, and others, and several applications including pharmaceutical, medical devices, research and development, and others.

What Is The Biopharmaceutical Tubing Market Growth Forecast?

The biopharmaceutical tubing market size is expected to see rapid growth in the next few years. It will grow to $8.12 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to growing pipeline of biologics and cell and gene therapy products, increasing shift toward single-use and disposable processing systems, higher demand for high-performance tpe and polyolefin tubing, expansion of automated production and closed system workflows, rising investment in advanced bioprocessing and aseptic transfer technologies. Major trends in the forecast period include increasing use of high-purity and biocompatible tubing in biopharmaceutical processing, rising adoption of single-use and sterile transfer tubing systems, growing demand for precision fluid handling in drug manufacturing and fill-finish operations, expansion of tubing applications across pharmaceutical, medical device, and r&d settings, focus on material durability, sterility assurance, and contamination control.

Global Biopharmaceutical Tubing Market Segmentation

1) By Product: Silicone Tubing, Polyvinyl Chloride (PVC) Tubing, Polyolefin Tubing, Thermoplastic Elastomer Tubing 2) By Manufacturing Process: Extrusion, Vulcanization, Other Manufacturing Processes 3) By Application: Pharmaceutical, Medical Devices, Research And Development, Other Applications Subsegments: 1) By Silicone Tubing: Medical-Grade Silicone Tubing, Platinum-Cured Silicone Tubing, Peroxide-Cured Silicone Tubing 2) By Polyvinyl Chloride (Pvc) Tubing: Clear Pvc Tubing, Non-Dehp Pvc Tubing, Soft Pvc Tubing 3) By Polyolefin Tubing: Cross-Linked Polyolefin Tubing, Low-Density Polyethylene Tubing, High-DDensity Polyethylene Tubing 4) By Thermoplastic Elastomer Tubing: Medical-Grade Tpe Tubing, Elastomeric Tpe Tubing, Biocompatible Tpe Tubing

What Is The Driver Of The Biopharmaceutical Tubing Market?

The increasing number of personalized medicines is expected to fuel the growth of the biopharmaceutical tubing market going forward. Personalized medicine refers to a medical approach that tailors healthcare decisions, practices, interventions, and treatments to the individual characteristics of each patient. Personalized medicine is in the light due to genetic research, which enables tailored treatment approaches based on an individual’s genetic profile, lifestyle, and specific health conditions. Biopharmaceutical tubing supports personalized medicine by providing precise, sterile, and reliable fluid transfer, essential for delivering customized treatments and therapies tailored to individual patient profiles. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized therapies in 2023, up from 18 in 2022, marking one of the highest annual gains in personalized medicine approvals. Therefore, the increasing number of personalized medicines is driving the growth of the biopharmaceutical tubing industry.

Key Players In The Global Biopharmaceutical Tubing Market

Major companies operating in the biopharmaceutical tubing market are Compagnie de Saint-Gobain S.A., Thermo Fisher Scientific Inc., Merck KGaA, GE HealthCare Technologies Inc., Parker Hannifin Corporation, DuPont de Nemours Inc., Freudenberg Group, Alfa Laval AB, REHAU Group, W. L. Gore & Associates Inc., Sartorius AG, Elkem ASA, Trelleborg AB, Bio-Rad Laboratories Inc., Tekni-Plex Inc., Pall Corporation, Zeus Company Inc., Watson-Marlow Ltd., Raumedic AG, Optinova AB, ESI Ultrapure

Global Biopharmaceutical Tubing Market Trends and Insights

Major companies operating in the biopharmaceutical tubing market are developing next-generation customizable solutions such as bioabsorbable tubing to enhance performance, improve sterility, and optimize fluid handling for advanced biopharmaceutical applications. Bioabsorbable tubing refers to specialized tubing made from materials that gradually break down and are absorbed by the body over time, eliminating the need for removal after use. For instance, in September 2023, Zeus Company Inc., a US-based advanced polymer solutions provider, launched the Absorv XSE-oriented tubing, a next-generation bioabsorbable product designed for bioresorbable vascular scaffolds (BRS). This enables medical device manufacturers to explore BRS applications beyond coronary artery disease treatment and potentially replace metallic stents in various procedures. The new tubing features improved uniformity in wall thickness and sizing, which results in greater efficiency during laser cutting processes, ultimately leading to more usable scaffolds.

What Are Latest Mergers And Acquisitions In The Biopharmaceutical Tubing Market?

In February 2024, EQT Private Equity, a Sweden-based investment management firm, completed the acquisition of Zeus Company Inc. for $3.4 billion. The acquisition enhances Zeus's growth by investing in additional production capacity, research and development, and operational excellence, particularly in medical tubing technology. Zeus Company Inc. is a US-based manufacturer specializing in precision polymer extrusions and custom tubing.

Regional Outlook

North America was the largest region in the biopharmaceutical tubing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Biopharmaceutical Tubing Market?

The biopharmaceutical tubing market consists of sales of polytetrafluoroethylene (PTFE) tubing, ethylene-vinyl acetate (EVA) tubing, and rubber tubing. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.